论文部分内容阅读
对泼尼松(P)/氢化泼尼松(PL)知识的增长是由于下列原因:首先是HPLC 方法的发展,使测定既方便又特异;其次,PL 和皮质素运载蛋白和白蛋白的非线性结合,而只有非结合PL 的浓度与生物学作用有关,因此有必要测定血浆中非结合分量的浓度;第三,PL 的半衰期很短,不能达到稳态,在研究中需要测定AUC;第四,P 和PL 可互相转化,PL 以酯型的前药静脉内给药,这些特点对正确解释药动学结果发生矛盾;最后,PL的全身清除率和非结合药物清除率随药浓度而增高,后者程度较轻。所以,为了比较个体药动学结果,必须给予标准药量。迄今的研究揭
The increase in knowledge of prednisone (P) / prednisolone (PL) is due to the following reasons: first is the development of HPLC methods that make assays both convenient and specific; and secondly, PL and cortistal and albumin non Linear binding, and only the concentration of non-conjugated PL is related to biological effects, so it is necessary to determine the concentration of non-binding components in plasma. Third, the half-life of PL is short and does not reach steady state. AUC needs to be determined in the study. Fourth, P and PL can be transformed into each other, PL is administered intravenously as an ester-type prodrug, and these characteristics contradict the correct interpretation of the pharmacokinetic results. Finally, the systemic clearance rate of the PL and the rate of non-binding drug clearance vary with the drug concentration Higher, the latter a lesser extent. Therefore, to compare individual pharmacokinetic results, a standard dose must be given. Research hitherto revealed